Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies.

Results of the meta-analysis In the randomized clinical trials, the FVC mean difference at 12 months between patients treated with CYC and patients treated with placebo or another immunosuppressant showed a positive trend in favor of the CYC group (mean difference = 4.15%), but did not reach statistical significance (95% confidence interval (CI) = -0.51 to 8.80; Figure 2a ).

also in 11,005 other papers